Search alternatives:
larger increases » large increases (Expand Search), marked increases (Expand Search), largest decreases (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 81 - 100 results of 19,984 for search '(( significantly ((larger increases) OR (larger decrease)) ) OR ( significant impact decrease ))', query time: 0.77s Refine Results
  1. 81
    Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.

    Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

    Published 2024
    “…The spatial information in dCA1 was significantly larger than circularly shuffled spike trains with similar mean firing rates for C57BL/6 mice (mean ± std: empirical = 0.132 ± 0.048, shuffled = 0.124 ± 0.035, p < 0.001, two-sided Wilcoxon rank-sum test, n<sub>empirical</sub> = 305 units from 5 recording sessions, n<sub>shuffled</sub> = 30500 simulated units from 5 recording sessions), but not for APP/PS1 mice (mean ± std: empirical = 0.128 ± 0.051, shuffled = 0.123 ± .047, p = 0.39, two-sided Wilcoxon rank-sum test, n<sub>empirical</sub> = 180 units from 4 recording sessions, n<sub>shuffled</sub> = 18000 simulated units from 4 recording sessions). …”
    Save to List
    Saved in:
  2. 82
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 83
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 84
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 85
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 86
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 87
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 88
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 89
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 90
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 91
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 92
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 93
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 94
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 95
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 96
    Distribution analysis results characterizing trends in immune gene expression with increasing propolis score for stationary and migratory operations across three sample dates.

    Distribution analysis results characterizing trends in immune gene expression with increasing propolis score for stationary and migratory operations across three sample dates. by Maggie Shanahan (17879479)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 97
    Participants’ prosocial behaviour over time.

    Participants’ prosocial behaviour over time. by Katie J. Shillington (16557695)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 98
    Flow diagram depicting shift in prosocial behaviour over the pandemic.

    Flow diagram depicting shift in prosocial behaviour over the pandemic. by Katie J. Shillington (16557695)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 99
    Examples of participants’ prosocial behaviour described during focus groups (n = 42).

    Examples of participants’ prosocial behaviour described during focus groups (n = 42). by Katie J. Shillington (16557695)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 100
    The prosocial behaviour and kindness of participants over time.

    The prosocial behaviour and kindness of participants over time. by Katie J. Shillington (16557695)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: